Bertrand Meresse

Dr. Bertrand Meresse

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2004 in Immunity
Verified
Journal Article
Closed access
BMBertrand Meresse
Bertrand Meresse
ZCZhangguo Chen
Zhangguo Chen
CCCezary Ciszewski
Cezary Ciszewski
MTMaria Tretiakova
Maria Tretiakova
GBGovind Bhagat
Govind Bhagat
BJBana Jabri
Bana Jabri

1 January 2009 in Gastroenterology
Verified
Journal Article
Closed access
GMGeorgia Malamut
Georgia Malamut
PAPauline Afchain
Pauline Afchain
VVVirginie Verkarre
Virginie Verkarre
TLThierry Lecomte
Thierry Lecomte
AAAurélien Amiot
Aurélien Amiot
CCChristophe Cellier
Christophe Cellier

8 May 2006 in Journal of Experimental Medicine
Verified
Journal Article
Open access
BMBertrand Meresse
Bertrand Meresse
SCShane A. Curran
Shane A. Curran
CCCezary Ciszewski
Cezary Ciszewski
GOGerasim Orbelyan
Gerasim Orbelyan
MSMala Setty
Mala Setty
BJBana Jabri
Bana Jabri
Celiac disease is an intestinal inflammatory disorder induced by dietary gluten in genetically susceptible individuals. The mechanisms underlying the massive expansion of interferon γ–producing intraepithelial cytotoxic T lymphocytes (CTLs) and the destruction of the epithelial cells lining the small intestine of celiac patients have remained elusive. We report massive oligoclonal expansions of intraepithelial CTLs that exhibit a profound genetic reprogramming of natural killer (NK) functions. These CTLs aberrantly expressed cytolytic NK lineage receptors, such as NKG2C, NKp44, and NKp46, which associate with adaptor molecules bearing immunoreceptor tyrosine-based activation motifs and induce ZAP-70 phosphorylation, cytokine secretion, and proliferation independently of T cell receptor signaling. This NK transformation of CTLs may underlie both the self-perpetuating, gluten-independent tissue damage and the uncontrolled CTL expansion leading to malignant lymphomas in severe forms of celiac disease. Because similar changes were detected in a subset of CTLs from cytomegalovirus-seropositive patients, we suggest that a stepwise transformation of CTLs into NK-like cells may underlie immunopathology in various chronic infectious and inflammatory diseases.

1 June 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GMGeorgia Malamut
Georgia Malamut
RMRaja El Machhour
Raja El Machhour
NMNicolas Montcuquet
Nicolas Montcuquet
SMSéverine Martin-Lannerée
Séverine Martin-Lannerée
IDIsabelle Dusanter-Fourt
Isabelle Dusanter-Fourt
BMBertrand Meresse
Bertrand Meresse
Enteropathy-associated T cell lymphoma is a severe complication of celiac disease (CD). One mechanism suggested to underlie its development is chronic exposure of intraepithelial lymphocytes (IELs) to potent antiapoptotic signals initiated by IL-15, a cytokine overexpressed in the enterocytes of individuals with CD. However, the signaling pathway by which IL-15 transmits these antiapoptotic signals has not been firmly established. Here we show that the survival signals delivered by IL-15 to freshly isolated human IELs and to human IEL cell lines derived from CD patients with type II refractory CD (RCDII) — a clinicopathological entity considered an intermediary step between CD and enteropathy-associated T cell lymphoma — depend on the antiapoptotic factors Bcl-2 and/or Bcl-xL. The signals also required IL-15Rβ, Jak3, and STAT5, but were independent of PI3K, ERK, and STAT3. Consistent with these data, IELs from patients with active CD and RCDII contained increased amounts of Bcl-xL, phospho-Jak3, and phospho-STAT5. Furthermore, incubation of patient duodenal biopsies with a fully humanized human IL-15–specific Ab effectively blocked Jak3 and STAT5 phosphorylation. In addition, treatment with this Ab induced IEL apoptosis and wiped out the massive IEL accumulation in mice overexpressing human IL-15 in their gut epithelium. Together, our results delineate the IL-15–driven survival pathway in human IELs and demonstrate that IL-15 and its downstream effectors are meaningful therapeutic targets in RCDII.

1 June 2012 in Immunity
Verified
Journal Article
Closed access
BMBertrand Meresse
Bertrand Meresse
GMGeorgia Malamut
Georgia Malamut
NCNadine Cerf-Bensussan
Nadine Cerf-Bensussan

1 September 2016 in Immunity
Verified
Journal Article
Closed access
JEJulien Ettersperger
Julien Ettersperger
NMNicolas Montcuquet
Nicolas Montcuquet
GMGeorgia Malamut
Georgia Malamut
NGNicolas Guegan
Nicolas Guegan
SLSilvia Lopez-Lastra
Silvia Lopez-Lastra
BMBertrand Meresse
Bertrand Meresse